EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation

MLA

Chang-Min Choi, et al. “EGFR-TKI Is Effective Regardless of Treatment Timing in Pulmonary Adenocarcinoma with EGFR Mutation.” Cancer Chemotherapy and Pharmacology, vol. 75, no. 1, May 2014. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d18ef0eda4d4c8da5ecb6b398fab4c1b&authtype=sso&custid=ns315887.

APA

Chang-Min Choi, Jung-Shin Lee, Se Jin Jang, Jae Cheol Lee, Sang-We Kim, Kyu-Pyo Kim, Dong Hoe Koo, & Dae Ho Lee. (2014). EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation. Cancer Chemotherapy and Pharmacology, 75(1).

Chicago

Chang-Min Choi, Jung-Shin Lee, Se Jin Jang, Jae Cheol Lee, Sang-We Kim, Kyu-Pyo Kim, Dong Hoe Koo, and Dae Ho Lee. 2014. “EGFR-TKI Is Effective Regardless of Treatment Timing in Pulmonary Adenocarcinoma with EGFR Mutation.” Cancer Chemotherapy and Pharmacology 75 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d18ef0eda4d4c8da5ecb6b398fab4c1b&authtype=sso&custid=ns315887.